Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban

Journal of Cardiology

Volumn 65, Issue 3, 2015, Pages 185-190

  Nakano, Yoshihisa ^a   Kondo, Takahisa ^a   Osanai, Hiroyuki ^b   Murase, Yosuke ^b   Nakashima, Yoshihito ^b   Asano, Hiroshi ^b   Ajioka, Masayoshi ^b   Sakai, Kazuyoshi ^b   Inden, Yasuya ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOSEI GENERAL HOSPITAL   (Japan)

Author keywords

Anticoagulant; Atrial fibrillation; Coagulation function; Rivaroxaban; Stroke prevention

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FIBRIN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD SAMPLING; CHADS2 SCORE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTHROMBIN TIME; ATRIAL FIBRILLATION; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; JAPAN; MIDDLE AGED; RISK; STROKE;

AGED; ATRIAL FIBRILLATION; FACTOR XA INHIBITORS; FEMALE; FIBRIN; HEMORRHAGE; HUMANS; JAPAN; MALE; MIDDLE AGED; PROTHROMBIN TIME; RISK; RIVAROXABAN; STROKE;

EID: 84924259748     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.07.021     Document Type: Article

References (24)

1. Wolf P.A., Abbott R.D., Kannel W.B. Atrial-fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
2. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
3. Ogawa S., Aizawa Y., Atarashi H., Inoue H., Kamakura S., Koretsune Y., Kumagai K., Mitamura H., Okumura K., Sugi K., Yamashita T., Yasaka M., Hiejima K., Kodama I., Ohe T., et al. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J 2010, 74:2479-2500.
4. Go A.S., Hylek E.M., Phillips K.A., Chang Y.C., Henault L.E., Selby J.V., Singer D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
5. Ohsawa M., Okayama A., Sakata K., Kato K., Itai K., Onoda T., Ueshima H. Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol 2005, 15:194-196.
6. Akao M., Chun Y.H., Wada H., Esato M., Hashimoto T., Abe M., Hasegawa K., Tsuji H., Furuke K. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 2013, 61:260-266.
7. Koudstaal P.J., Vanlatum J.C., Vangijn J., Kappelle L.J., Algra A., Dehaene I., Dhooghe M., Marchau M., Vanzandijcke M., Delwaide C., Depre A., Laterre E.C., Vanbuggenhout E., Schurmans J., Desmet E., et al. Optimal oral anticoagulant-therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995, 333:5-10.
8. Yasaka M., Minematsu K., Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001, 40:1183-1188.
9. Inoue H., Okumura K., Atarashi H., Yamashita T., Origasa H., Kumagai N., Sakurai M., Kawamura Y., Kubota I., Matsumoto K., Kaneko Y., Ogawa S., Aizawa Y., Chinushi M., Kodama I., et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J 2013, 77:2264-2270.
10. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
11. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
12. Granger C.B., Alexander J.H., McMurray J.J.V., Lopes R.D., Hylek E.M., Hanna M., Al-Khalidi H.R., Ansell J., Atar D., Avezum A., Cecilia Bahit M., Diaz R., Easton J.D., Ezekowitz J.A., Flaker G., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
13. Heidbuchel H., Verhamme P., Alings M., Antz M., Hacke W., Oldgren J., Sinnaeve P., Camm A.J., Kirchhof P. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013, 15:625-651.
14. Hori M., Matsumoto M., Tanahashi N., Momomura S., Uchiyama S., Goto S., Izumi T., Koretsune Y., Kajikawa M., Kato M., Ueda H., Iwamoto K., Tajiri M. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 2012, 76:2104-2111.
15. Hillarp A., Baghaei F., Blixter I.F., Gustafsson K.M., Stigendal L., Sten-Linder M., Strandberg K., Lindahl T.L. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9:133-139.
16. Lindhoff-Last E., Samama M.M., Ortel T.L., Weitz J.I., Spiro T.E. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010, 32:673-679.
17. Samama M.M., Martinoli J.L., LeFlem L., Guinet C., Plu-Bureau G., Depasse F., Perzborn E. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
18. Molenaar P.J., Dinkelaar J., Leyte A. Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 2012, 50:1799-1807.
19. Suzuki S., Otsuka T., Sagara K., Kano H., Matsuno S., Kato Y., Takai H., Uejima T., Oikawa Y., Nagashima K., Kirigaya H., Yajima J., Sawada H., Aizawa T., Yamashita T. Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time. Circ J 2014, 78:763-766.
20. Dempfle C.E. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 1999, 82:673-683.
21. Sudo A., Wada H., Nobori T., Yamada N., Ito M., Niimi R., Hasegawa M., Suzuki K., Uchida A. Cut-off values of d-dimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery. Int J Hematol 2009, 89:572-576.
22. Tsuji A., Wada H., Matsumoto T., Abe Y., Ota S., Yamada N., Sugiyama T., Sudo A., Onishi K., Nakatani K., Uchida A., Ito M., Suzuki K., Nobori T. Elevated levels of soluble fibrin in patients with venous thromboembolism. Int J Hematol 2008, 88:448-453.
23. Fox K.A.A., Piccini J.P., Wojdyla D., Becker R.C., Halperin J.L., Nessel C.C., Paolini J.F., Hankey G.J., Mahaffey K.W., Patel M.R., Singer D.E., Califf R.M. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32:2387-2394.
24. Tanigawa T., Kaneko M., Hashizume K., Kajikawa M., Ueda H., Tajiri M., Paolini J.F., Mueck W. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet 2013, 28:59-70.